Should You Buy Titan Pharmaceuticals, Inc. common stock (TTNP) Stock After it Is Higher By 10.20% in a Week?

Friday, October 28, 2022 01:30 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Titan Pharmaceuticals, Inc. common stock (TTNP) Stock After it Is Higher By 10.20% in a Week?

Titan Pharmaceuticals, Inc. common stock (TTNP) stock is higher by 10.20% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Titan Pharmaceuticals, Inc. common stock has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TTNP!

See Full TTNP Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With TTNP Stock Today?

Titan Pharmaceuticals, Inc. common stock (TTNP) stock is trading at $1.08 as of 12:54 PM on Friday, Oct 28, an increase of $0.06, or 5.88% from the previous closing price of $1.02. The stock has traded between $1.03 and $1.14 so far today. Volume today is light. So far 16,760 shares have traded compared to average volume of 29,243 shares. To see InvestorsObserver's Sentiment Score for Titan Pharmaceuticals, Inc. common stock click here.

More About Titan Pharmaceuticals, Inc. common stock

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. Click Here to get the full Stock Report for Titan Pharmaceuticals, Inc. common stock stock.